1. Home
  2. NREF vs FULC Comparison

NREF vs FULC Comparison

Compare NREF & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Real Estate Finance Inc.

NREF

NexPoint Real Estate Finance Inc.

HOLD

Current Price

$17.13

Market Cap

296.5M

Sector

Real Estate

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.88

Market Cap

285.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NREF
FULC
Founded
2019
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
296.5M
285.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NREF
FULC
Price
$17.13
$3.88
Analyst Decision
Hold
Buy
Analyst Count
2
8
Target Price
$14.00
$16.38
AVG Volume (30 Days)
44.5K
1.5M
Earning Date
04-30-2026
04-27-2026
Dividend Yield
13.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.47
N/A
P/E Ratio
$4.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.36
$2.83
52 Week High
$18.43
$15.74

Technical Indicators

Market Signals
Indicator
NREF
FULC
Relative Strength Index (RSI) 55.31 54.15
Support Level $16.39 $3.44
Resistance Level $17.22 $3.96
Average True Range (ATR) 0.58 0.14
MACD -0.07 0.03
Stochastic Oscillator 36.29 89.77

Price Performance

Historical Comparison
NREF
FULC

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: